No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Alvotech Acquires Xbrane’s Swedish R&D Operations & Biosimilar Peg-Certolizumab
On 20 March 2025, Alvotech announced its acquisition of Xbrane’s Swedish R&D operations, as well as biosimilar candidate XB003 referencing UCB’s Cimzia® (certolizumab pegol). Xbrane will retain…